Osteoarthritis - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 264 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Osteoarthritis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Osteoarthritis - Pipeline Review, H2 2014', provides an overview of the Osteoarthritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteoarthritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Osteoarthritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Osteoarthritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Osteoarthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Osteoarthritis Overview 11
Therapeutics Development 12
Pipeline Products for Osteoarthritis - Overview 12
Pipeline Products for Osteoarthritis - Comparative Analysis 13
Osteoarthritis - Therapeutics under Development by Companies 14
Osteoarthritis - Therapeutics under Investigation by Universities/Institutes 20
Osteoarthritis - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Osteoarthritis - Products under Development by Companies 24
Osteoarthritis - Products under Investigation by Universities/Institutes 30
Osteoarthritis - Companies Involved in Therapeutics Development 31
Seikagaku Corporation 31
Sanofi 32
Advanced Cell Technology, Inc. 33
TiGenix NV 34
Novartis AG 35
Astellas Pharma Inc. 36
Chong Kun Dang Pharmaceutical Corp. 37
Teva Pharmaceutical Industries Limited 38
A. Menarini Industrie Farmaceutiche Riunite Srl 39
Merck KGaA 40
Bone Medical Limited 41
Addex Therapeutics Ltd 42
Can-Fite BioPharma Ltd. 43
Medivir AB 44
Mesoblast Limited 45
Calzada Limited 46
NicOx S.A. 47
Osteologix Holdings Plc. 48
Yungjin Pharm Ind. Co., Ltd. 49
Yuhan Corporation 50
Galapagos NV 51
CrystalGenomics, Inc. 52
Biopharm GmbH 53
Upsher-Smith Laboratories, Inc. 54
Abiogen Pharma S.p.A. 55
Amura Holdings Ltd. 56
PLx Pharma Inc. 57
TissueGene, Inc. 58
Rottapharm SpA 59
Cardax Pharmaceuticals, Inc. 60
Nordic Bioscience a/s 61
Omeros Corporation 62
Cellceutix Corporation 63
Asklepios BioPharmaceutical, Inc. 64
TOKUHON Corporation 65
K-Stemcell Co., Ltd. 66
ReqMed Company, Ltd. 67
Laila Pharmaceuticals Pvt. Ltd. 68
Bioiberica, S.A. 69
Stempeutics Research Private Limited 70
Ampio Pharmaceuticals, Inc. 71
Arcarios BV 72
OrthoCyte Corporation 73
IntelliCell BioSciences Inc. 74
Evgen Limited 75
AbbVie Inc. 76
Genequine Biotherapeutics GmbH 77
Cellular Biomedicine Group, Inc. 78
Voltarra Pharmaceuticals, Inc. 79
Osteoarthritis - Therapeutics Assessment 80
Assessment by Monotherapy Products 80
Assessment by Combination Products 81
Assessment by Target 82
Assessment by Mechanism of Action 86
Assessment by Route of Administration 90
Assessment by Molecule Type 92
Drug Profiles 94
polmacoxib - Drug Profile 94
naproxcinod - Drug Profile 96
TG-C - Drug Profile 98
flurbiprofen - Drug Profile 100
Ampion - Drug Profile 101
clodronate disodium - Drug Profile 103
VOLT-01 - Drug Profile 104
(amlodipine besylate + celecoxib) - Drug Profile 105
sprifermin - Drug Profile 106
Chondrogen - Drug Profile 108
CF-101 - Drug Profile 109
TV-45070 - Drug Profile 112
TG-C - Drug Profile 113
calcitonin - Drug Profile 115
PL-1100 - Drug Profile 117
PRX-167700 - Drug Profile 118
fasitibant chloride - Drug Profile 119
Stempeucel - Drug Profile 121
MSB-CAR-001 - Drug Profile 124
pentosan polysulfate sodium - Drug Profile 125
Jointstem - Drug Profile 126
ABT-981 - Drug Profile 127
pentosan polysulfate sodium - Drug Profile 128
SI-613 - Drug Profile 129
ReJoin - Drug Profile 130
WIN-34B - Drug Profile 131
TPX-100 - Drug Profile 132
X-0002 - Drug Profile 134
Stem Cell Therapy - Drug Profile 136
Stem Cell Therapy for Osteoarthritis - Drug Profile 138
Protein for Osteoarthritis and Asthma - Drug Profile 139
Cell Therapy for Immunological Diseases - Drug Profile 140
APIC-CF - Drug Profile 141
MIV-711 - Drug Profile 142
Jointstem - Drug Profile 143
ASP-7962 - Drug Profile 144
(clodronate + hyaluronic acid) - Drug Profile 145
SM-04690 - Drug Profile 146
ASP-3700 - Drug Profile 148
(naproxen + anti-hypertensive agent) - Drug Profile 149
CHND-1 - Drug Profile 150
AOD-9604 - Drug Profile 152
SAR-396049 - Drug Profile 154
KM-278 - Drug Profile 155
MIV-710 - Drug Profile 156
CRB-0016 - Drug Profile 157
MOR-106 - Drug Profile 158
CDX-085 - Drug Profile 159
GLPG-1972 - Drug Profile 161
KBP-088 - Drug Profile 162
AM-3701 - Drug Profile 164
AM-3876 - Drug Profile 165
OTX-CP07 - Drug Profile 166
Cx-603 - Drug Profile 167
OTX-CP03 - Drug Profile 168
YH-14619 - Drug Profile 169
ASP-6537 - Drug Profile 170
Sulforadex - Drug Profile 172
ARC-118 - Drug Profile 173
Autologous Vascular Cells Therapy - Drug Profile 174
GQ-203 - Drug Profile 175
Kartogenin - Drug Profile 176
Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - Drug Profile 177
Stem Cell Therapy for Osteoarthritis and Articular Cartilage Defect - Drug Profile 178
CRB-0017 - Drug Profile 179
Stromal Cell Therapy For Arthritis - Drug Profile 180
AS-001 - Drug Profile 181
Stem Cell Therapy For Osteoarthritis - Drug Profile 182
XT-101 - Drug Profile 183
CR-6086 - Drug Profile 184
Drugs to Inhibit Complement System Protein for Osteoarthritis - Drug Profile 185
Stem Cell Therapy for Knee Osteoarthritis - Drug Profile 186
Monoclonal Antibody for Osteoarthritis - Drug Profile 187
Drugs to Inhibit Renin Angiotensin for Osteo Arthritis - Drug Profile 188
Adipose Stem Cell Therapy for Degenerative Arthritis - Drug Profile 189
Inulin Polysulfate - Drug Profile 190
Anatabine - Drug Profile 191
YRA-1909 - Drug Profile 192
GQ-303 - Drug Profile 193
ECPF-1 - Drug Profile 194
NBS-101 - Drug Profile 195
CR-5259 Series - Drug Profile 197
CR-5790 Series - Drug Profile 198
CR-4174 Series - Drug Profile 199
Small Molecules to Inhibit TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders - Drug Profile 200
Small Molecule Targeting A2A-PAM for Immunology Disorders - Drug Profile 201
Small Molecule Targeting GPR22 for Osteoarthritis - Drug Profile 202
Bone Morphogenetic Protein Modulators - Drug Profile 203
Drug for Bone Diseases and Osteoarthritis - Drug Profile 204
BNP-OA - Drug Profile 205
DIS-BIO-EPS - Drug Profile 206
LP-00509 - Drug Profile 207
VA-964 - Drug Profile 208
CR-8357 - Drug Profile 209
Recombinant Protein to Activate IL-4 and IL-10 Receptors for Osteoarthritis - Drug Profile 210
Protein for Osteoarthritis - Drug Profile 211
Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 212
Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 213
Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile 214
Small Molecules to Inhibit Kinase for Osteoarthritis and Osteoporosis - Drug Profile 215
Osteoarthritis - Recent Pipeline Updates 216
Osteoarthritis - Dormant Projects 241
Osteoarthritis - Discontinued Products 248
Osteoarthritis - Product Development Milestones 249
Featured News & Press Releases 249
Appendix 256
Methodology 256
Coverage 256
Secondary Research 256
Primary Research 256
Expert Panel Validation 256
Contact Us 257
Disclaimer 257

List of Tables
Number of Products under Development for Osteoarthritis, H2 2014 19
Number of Products under Development for Osteoarthritis - Comparative Analysis, H2 2014 20
Number of Products under Development by Companies, H2 2014 22
Number of Products under Development by Companies, H2 2014 (Contd..1) 23
Number of Products under Development by Companies, H2 2014 (Contd..2) 24
Number of Products under Development by Companies, H2 2014 (Contd..3) 25
Number of Products under Development by Companies, H2 2014 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H2 2014 27
Comparative Analysis by Late Stage Development, H2 2014 28
Comparative Analysis by Clinical Stage Development, H2 2014 29
Comparative Analysis by Early Stage Development, H2 2014 30
Products under Development by Companies, H2 2014 31
Products under Development by Companies, H2 2014 (Contd..1) 32
Products under Development by Companies, H2 2014 (Contd..2) 33
Products under Development by Companies, H2 2014 (Contd..3) 34
Products under Development by Companies, H2 2014 (Contd..4) 35
Products under Development by Companies, H2 2014 (Contd..5) 36
Products under Investigation by Universities/Institutes, H2 2014 37
Osteoarthritis - Pipeline by Seikagaku Corporation, H2 2014 38
Osteoarthritis - Pipeline by Sanofi, H2 2014 39
Osteoarthritis - Pipeline by Advanced Cell Technology, Inc., H2 2014 40
Osteoarthritis - Pipeline by TiGenix NV, H2 2014 41
Osteoarthritis - Pipeline by Novartis AG, H2 2014 42
Osteoarthritis - Pipeline by Astellas Pharma Inc., H2 2014 43
Osteoarthritis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 44
Osteoarthritis - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 45
Osteoarthritis - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 46
Osteoarthritis - Pipeline by Merck KGaA, H2 2014 47
Osteoarthritis - Pipeline by Bone Medical Limited, H2 2014 48
Osteoarthritis - Pipeline by Addex Therapeutics Ltd, H2 2014 49
Osteoarthritis - Pipeline by Can-Fite BioPharma Ltd., H2 2014 50
Osteoarthritis - Pipeline by Medivir AB, H2 2014 51
Osteoarthritis - Pipeline by Mesoblast Limited, H2 2014 52
Osteoarthritis - Pipeline by Calzada Limited, H2 2014 53
Osteoarthritis - Pipeline by NicOx S.A., H2 2014 54
Osteoarthritis - Pipeline by Osteologix Holdings Plc., H2 2014 55
Osteoarthritis - Pipeline by Yungjin Pharm Ind. Co., Ltd., H2 2014 56
Osteoarthritis - Pipeline by Yuhan Corporation, H2 2014 57
Osteoarthritis - Pipeline by Galapagos NV, H2 2014 58
Osteoarthritis - Pipeline by CrystalGenomics, Inc., H2 2014 59
Osteoarthritis - Pipeline by Biopharm GmbH, H2 2014 60
Osteoarthritis - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 61
Osteoarthritis - Pipeline by Abiogen Pharma S.p.A., H2 2014 62
Osteoarthritis - Pipeline by Amura Holdings Ltd., H2 2014 63
Osteoarthritis - Pipeline by PLx Pharma Inc., H2 2014 64
Osteoarthritis - Pipeline by TissueGene, Inc., H2 2014 65
Osteoarthritis - Pipeline by Rottapharm SpA, H2 2014 66
Osteoarthritis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2014 67
Osteoarthritis - Pipeline by Nordic Bioscience a/s, H2 2014 68
Osteoarthritis - Pipeline by Omeros Corporation, H2 2014 69
Osteoarthritis - Pipeline by Cellceutix Corporation, H2 2014 70
Osteoarthritis - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2014 71
Osteoarthritis - Pipeline by TOKUHON Corporation, H2 2014 72
Osteoarthritis - Pipeline by K-Stemcell Co., Ltd., H2 2014 73
Osteoarthritis - Pipeline by ReqMed Company, Ltd., H2 2014 74
Osteoarthritis - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H2 2014 75
Osteoarthritis - Pipeline by Bioiberica, S.A., H2 2014 76
Osteoarthritis - Pipeline by Stempeutics Research Private Limited, H2 2014 77
Osteoarthritis - Pipeline by Ampio Pharmaceuticals, Inc., H2 2014 78
Osteoarthritis - Pipeline by Arcarios BV, H2 2014 79
Osteoarthritis - Pipeline by OrthoCyte Corporation, H2 2014 80
Osteoarthritis - Pipeline by IntelliCell BioSciences Inc., H2 2014 81
Osteoarthritis - Pipeline by Evgen Limited, H2 2014 82
Osteoarthritis - Pipeline by AbbVie Inc., H2 2014 83
Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH, H2 2014 84
Osteoarthritis - Pipeline by Cellular Biomedicine Group, Inc., H2 2014 85
Osteoarthritis - Pipeline by Voltarra Pharmaceuticals, Inc., H2 2014 86
Assessment by Monotherapy Products, H2 2014 87
Assessment by Combination Products, H2 2014 88
Number of Products by Stage and Target, H2 2014 91
Number of Products by Stage and Mechanism of Action, H2 2014 95
Number of Products by Stage and Route of Administration, H2 2014 98
Number of Products by Stage and Molecule Type, H2 2014 100
Osteoarthritis Therapeutics - Recent Pipeline Updates, H2 2014 223
Osteoarthritis - Dormant Projects, H2 2014 248
Osteoarthritis - Dormant Projects (Contd..1), H2 2014 249
Osteoarthritis - Dormant Projects (Contd..2), H2 2014 250
Osteoarthritis - Dormant Projects (Contd..3), H2 2014 251
Osteoarthritis - Dormant Projects (Contd..4), H2 2014 252
Osteoarthritis - Dormant Projects (Contd..5), H2 2014 253
Osteoarthritis - Dormant Projects (Contd..6), H2 2014 254
Osteoarthritis - Discontinued Products, H2 2014 255